Study on the ef ficacy of recombinant hepatitis b vaccine in iranian infants

In order to determine the efficacy of recombinant hepatitis B vaccine in Ira­ nian infants, we analyzed the efficacy of a recombinant hepatitis B vaccine in 115 infants aged 12-24 months born to HBsAg negative mothers who received three doses of HBV Antibody to hepatitis B surface antigen (anti-HBs) was checked after the third dose of the vaccine, 94.8% of the infants had developed protective antibody levels. The vaccine was well-tolerated and no serious adverse effects were reported. This study is in agreement with a WHO report which recommends that the easiest and most cost-effective strategy for the control and eventual eradication of HBV would be to immunize all newborns with hepatitis B vaccine only [World Health Organization report, 1984]. MJIRI, Vol. 14, No.4, 347-349, 2001.